$2.94
17.13%
Nasdaq, Sep 05, 10:18 pm CET
ISIN
US38341P1021
Symbol
GOSS

Gossamer Bio, Inc. Target price 2025 - Analyst rating & recommendation

Gossamer Bio, Inc. Classifications & Recommendation:

Buy
80%
Hold
20%

Gossamer Bio, Inc. Price Target

Target Price $8.16
Price $2.94
Potential
Number of Estimates 9
9 Analysts have issued a price target Gossamer Bio, Inc. 2026 . The average Gossamer Bio, Inc. target price is $8.16. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 12 Analysts recommend Gossamer Bio, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Gossamer Bio, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 114.70 36.35
68.31%
EBITDA Margin -48.62% -402.56%
727.93%
Net Margin -49.29% -424.10%
760.50%

11 Analysts have issued a sales forecast Gossamer Bio, Inc. 2025 . The average Gossamer Bio, Inc. sales estimate is

$36.4m
Unlock
. This is
9.66% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$70.1m 74.30%
Unlock
, the lowest is
$21.0m 47.93%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $115m
2025
$36.4m 68.31%
Unlock
2026
$47.5m 30.65%
Unlock
2027
$120m 151.91%
Unlock
2028
$237m 98.30%
Unlock
2029
$392m 65.40%
Unlock
2030
$706m 79.87%
Unlock
2031
$726m 2.89%
Unlock
2032
$901m 24.10%
Unlock

5 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2025. The average Gossamer Bio, Inc. EBITDA estimate is

$-146m
Unlock
. This is
3.47% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-120m 15.22%
Unlock
, the lowest is
$-169m 19.69%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-55.8m 67.07%
2025
$-146m 162.39%
Unlock
2026
$-43.6m 70.19%
Unlock
2027
$26.9m 161.56%
Unlock
2028
$67.9m 152.98%
Unlock
2029
$157m 130.77%
Unlock
2030
$297m 89.40%
Unlock

EBITDA Margin

2024 -48.62%
2025
-402.56% 727.93%
Unlock
2026
-91.84% 77.19%
Unlock
2027
22.44% 124.43%
Unlock
2028
28.63% 27.58%
Unlock
2029
39.95% 39.54%
Unlock
2030
42.07% 5.31%
Unlock

11 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2025. The average Gossamer Bio, Inc. net profit estimate is

$-154m
Unlock
. This is
11.11% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-122m 12.26%
Unlock
, the lowest is
$-172m 23.64%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-56.5m 68.56%
2025
$-154m 172.70%
Unlock
2026
$-113m 26.84%
Unlock
2027
$-61.4m 45.52%
Unlock
2028
$18.0m 129.25%
Unlock
2029
$72.5m 303.23%
Unlock
2030
$108m 48.80%
Unlock
2031
$173m 60.75%
Unlock
2032
$231m 33.11%
Unlock

Net Margin

2024 -49.29%
2025
-424.10% 760.50%
Unlock
2026
-237.45% 44.01%
Unlock
2027
-51.36% 78.37%
Unlock
2028
7.57% 114.74%
Unlock
2029
18.46% 143.86%
Unlock
2030
15.28% 17.23%
Unlock
2031
23.87% 56.22%
Unlock
2032
25.60% 7.25%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.25 -0.68
78.81% 172.00%
P/E negative
EV/Sales 17.98

11 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is

$-0.68
Unlock
. This is
11.48% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.54 11.48%
Unlock
, the lowest is
$-0.75 22.95%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.25 78.81%
2025
$-0.68 172.00%
Unlock
2026
$-0.50 26.47%
Unlock
2027
$-0.27 46.00%
Unlock
2028
$0.08 129.63%
Unlock
2029
$0.32 300.00%
Unlock
2030
$0.47 46.88%
Unlock
2031
$0.76 61.70%
Unlock
2032
$1.01 32.89%
Unlock

P/E ratio

Current -4.82 81.19%
2025
-4.34 9.95%
Unlock
2026
-5.93 36.64%
Unlock
2027
-10.88 83.47%
Unlock
2028
37.19 441.82%
Unlock
2029
9.22 75.21%
Unlock
2030
6.20 32.75%
Unlock
2031
3.86 37.74%
Unlock
2032
2.90 24.87%
Unlock

Based on analysts' sales estimates for 2025, the Gossamer Bio, Inc. stock is valued at an EV/Sales of

17.98
Unlock
and an P/S ratio of
18.39
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 16.24 3,676.74%
2025
17.98 10.71%
Unlock
2026
13.76 23.46%
Unlock
2027
5.46 60.30%
Unlock
2028
2.75 49.57%
Unlock
2029
1.67 39.54%
Unlock
2030
0.93 44.40%
Unlock
2031
0.90 2.81%
Unlock
2032
0.73 19.42%
Unlock

P/S ratio

Current 16.61 701.78%
2025
18.39 10.70%
Unlock
2026
14.08 23.46%
Unlock
2027
5.59 60.30%
Unlock
2028
2.82 49.57%
Unlock
2029
1.70 39.54%
Unlock
2030
0.95 44.41%
Unlock
2031
0.92 2.81%
Unlock
2032
0.74 19.41%
Unlock

Current Gossamer Bio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wedbush
Locked
Locked
Locked Aug 06 2025
Scotiabank
Locked
Locked
Locked Jul 14 2025
Goldman Sachs
Locked
Locked
Locked May 16 2025
Wedbush
Locked
Locked
Locked May 16 2025
Goldman Sachs
Locked
Locked
Locked Apr 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 18 2025
Wedbush
Locked
Locked
Locked Mar 14 2025
Analyst Rating Date
Locked
Wedbush:
Locked
Locked
Aug 06 2025
Locked
Scotiabank:
Locked
Locked
Jul 14 2025
Locked
Goldman Sachs:
Locked
Locked
May 16 2025
Locked
Wedbush:
Locked
Locked
May 16 2025
Locked
Goldman Sachs:
Locked
Locked
Apr 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 18 2025
Locked
Wedbush:
Locked
Locked
Mar 14 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today